The treatment of human DNMT3A mutant AML cell lines, xenograft models, and leukemic stem cells with DOT1L inhibitors led to reduced proliferation, cell cycle arrest, and differentiation [117,118]. The gene discussed is DOT1L; the disease is acute myeloid leukemia.